Key statistics
On Thursday, Beigene Ltd (BGNE:NSQ) closed at 194.56, -21.60% below its 52-week high of 248.16, set on Oct 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 196.09 |
---|---|
High | 197.48 |
Low | 191.41 |
Bid | 180.00 |
Offer | 202.94 |
Previous close | 194.26 |
Average volume | 289.50k |
---|---|
Shares outstanding | 106.25m |
Free float | 102.50m |
P/E (TTM) | -- |
Market cap | 21.70bn USD |
EPS (TTM) | -8.24 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
- BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
- BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
- BeiGene to Present at the Jefferies London Healthcare Conference
- BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
- BeiGene Mourns Death of Beloved Board Member Donald Glazer
- BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
- BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
- BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
- Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
More ▼